Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

JAMA - 12 Oct 2011

Yang Da, Khan Sofia, Sun Yan, Hess Kenneth, Shmulevich Ilya, Sood Anil K, Zhang Wei

Abstract excerpt

CONTEXT: Attempts to determine the clinical significance of BRCA1/2 mutations in ovarian cancer have produced conflicting results. OBJECTIVE: To determine the relationships between BRCA1/2 deficiency (ie, mutation and promoter hypermethylation) and overall survival (OS), progression-free survival (PFS), chemotherapy response, and whole-exome mutation rate in ovarian cancer. DESIGN, SETTING, AND PATIENTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Databases, Factual
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Genomic Instability

Share to Ovarian Neoplasms

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 21990299
DOI: 10.1001/jama.2011.1456
PMCID: PMC4159096

Genes

BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.PMID 21990299Read ↗

The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.Semantic proximity Read ↗

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcomeSemantic proximity Read ↗

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.Semantic proximity Read ↗

g BRCA1 and g BRCA2 mutations in specific different domains affect ovarian cancer prognosis: A multicenter retrospective study.Semantic proximity Read ↗

Detection of BRCA1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of Ovarian Cancer.Semantic proximity Read ↗

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.Semantic proximity Read ↗

Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer.Semantic proximity Read ↗

Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta-analysis.Semantic proximity Read ↗

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.Semantic proximity Read ↗

A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.